Skip to main content

Table 5 Survival endpoints using RECIST or combined criteria

From: Image-based response assessment of liver metastases following stereotactic body radiotherapy with respiratory tracking

Survival endpoints

   RECIST

   Combined criteria

Overall Survival

  Death

8

  Median [CI 95%]

-

  OS rate, % [CI 95%]

  

  12 months

           96 [77.2-99.5]

  18 months

             72. [51–86]

  24 months

             67 [44–82]

Progression-Free Survival

  

 Progression or Death (every cause)

14

15

 Median [CI 95%]

19.3 [8.0-…]

19.1 [12.3-…]

 PFS rate, % [CI 95%]

  

  12 months

68 [47–82]

71 [51–85]

  18 months

56 [36–72]

52 [32–69]

  24 months

47 [27–65]

43 [24–61]

Time to Progression

  

 Progression or death from disease progression

13

13

 Median [CI 95%]

-

19.3 [12.3-…]

 TTP rate, % [CI 95%]

  

  12 months

68 [47–82]

71 [51–85]

  18 months

60 [40–76]

60 [39–75]

  24 months

51 [30–68]

49 [28–67]